Aquestive Therapeutics Q1 Revenues Up 66%, Net Loss Narrows to $8.1M
Aquestive Therapeutics posted a 66% revenue increase in Q1 2026 driven by higher license and royalty revenues, while net loss narrowed to $8.1 million. FDA human factors review and reimbursement challenges leave Anaphylm’s approval timeline uncertain, though company targets Canada, UK and EU filings without extra clinical studies.
1. Q1 2026 Financial Performance
In the first quarter of 2026, Aquestive reported a 66% year-over-year increase in total revenues driven by higher license and royalty fees, while net loss improved to $8.1 million compared with the prior year period.
2. Anaphylm Approval and Launch Uncertainty
The company’s lead candidate, Anaphylm, remains subject to FDA human factors protocol review, creating an uncertain US approval timeline, and executives highlight that establishing coverage and reimbursement will be a multi-year effort.
3. International Expansion Plans
Aquestive is preparing filings for Anaphylm in Canada, the UK and the EU using existing clinical data without new studies, and is engaging potential regional partners to negotiate market access and commercialization economics.
4. AQST-108 Biomarker Progress
Early biomarker analysis for AQST-108 shows a TSLP signal crossing both Th1 and Th2 inflammatory pathways, indicating potential in alopecia areata and atopic dermatitis, and plans are in place to expand these immunomodulatory studies.